HK1245111A1 - IL-1β抗体及其结合片段的心血管相关用途 - Google Patents

IL-1β抗体及其结合片段的心血管相关用途 Download PDF

Info

Publication number
HK1245111A1
HK1245111A1 HK18104608.6A HK18104608A HK1245111A1 HK 1245111 A1 HK1245111 A1 HK 1245111A1 HK 18104608 A HK18104608 A HK 18104608A HK 1245111 A1 HK1245111 A1 HK 1245111A1
Authority
HK
Hong Kong
Prior art keywords
antibody
binding
fragment
binding fragment
cardiovascular
Prior art date
Application number
HK18104608.6A
Other languages
English (en)
Chinese (zh)
Inventor
Patrick J. Scannon
Alan M. Solinger
Jeffrey D. Feldstein
Original Assignee
Xoma (Us) Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma (Us) Llc filed Critical Xoma (Us) Llc
Publication of HK1245111A1 publication Critical patent/HK1245111A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK18104608.6A 2009-05-29 2018-04-09 IL-1β抗体及其结合片段的心血管相关用途 HK1245111A1 (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US18267909P 2009-05-29 2009-05-29
US61/182,679 2009-05-29
US25257109P 2009-10-16 2009-10-16
US61/252,571 2009-10-16
US31300110P 2010-03-11 2010-03-11
US61/313,001 2010-03-11

Publications (1)

Publication Number Publication Date
HK1245111A1 true HK1245111A1 (zh) 2018-08-24

Family

ID=43223130

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18104608.6A HK1245111A1 (zh) 2009-05-29 2018-04-09 IL-1β抗体及其结合片段的心血管相关用途

Country Status (15)

Country Link
US (3) US20100316651A1 (enExample)
EP (1) EP2435073A4 (enExample)
JP (2) JP5763625B2 (enExample)
KR (1) KR20120061041A (enExample)
CN (2) CN107243077A (enExample)
AU (1) AU2010253924B2 (enExample)
BR (1) BRPI1011228A2 (enExample)
CA (1) CA2763161A1 (enExample)
EA (1) EA201101643A1 (enExample)
HK (1) HK1245111A1 (enExample)
IL (1) IL216660A0 (enExample)
MX (1) MX2011012666A (enExample)
NZ (1) NZ597024A (enExample)
SG (3) SG10201500180RA (enExample)
WO (1) WO2010138939A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013025368A8 (pt) * 2011-04-01 2018-06-12 The Medicines Co Medicamento, método para preparar um medicamento útil para reduzir danos por derrame em um sujeito com derrame, método para preparar um medicamento útil para reduzir a pressão sanguínea e reduzir danos por derrame em um sujeito com derrame
BR112014007253A2 (pt) * 2011-09-30 2017-03-28 Novartis Ag uso de anticorpos que se ligam a il-1beta
PL2623604T3 (pl) * 2012-02-02 2015-07-31 Baylor College Medicine Biologiczny system dostarczania i ekspresji oparty na adenowirusie do zastosowania w leczeniu choroby zwyrodnieniowej stawów
CN103588878A (zh) * 2012-08-15 2014-02-19 江苏泰康生物医药有限公司 一种人源化抗人白细胞介素1 β单克隆抗体及其制备与应用
EP4628162A3 (en) * 2012-10-04 2025-12-03 XBiotech Inc. Treating vascular disease and complications thereof
US10000565B2 (en) 2012-11-16 2018-06-19 Novartis Ag Use of IL-1 β binding antibodies for treating peripheral arterial disease
US10000557B2 (en) * 2012-12-19 2018-06-19 Dnae Group Holdings Limited Methods for raising antibodies
CN103059136A (zh) * 2012-12-24 2013-04-24 浙江大学 抗中华鳖IL-1β多克隆抗体的制备及在检测中的应用
KR102337954B1 (ko) * 2018-08-16 2021-12-10 차의과학대학교 산학협력단 뇌졸중 치료용 조성물 및 이를 스크리닝하는 방법
CN113874034A (zh) * 2019-05-03 2021-12-31 苏黎世大学 脑缺血再灌注损伤的治疗
US20220275079A1 (en) * 2020-11-20 2022-09-01 The General Hospital Corporation Clonal Hematopoiesis and Risk of Chronic Liver Disease
GB202400340D0 (en) 2024-01-10 2024-02-21 Wotherspoon Hugh Robert IL-1B binding antibody

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820383B2 (en) * 1997-03-10 2010-10-26 Interleukin Genetics, Inc. Method for diagnosing myocardial infarction
AR016551A1 (es) * 1997-07-30 2001-07-25 Smithkline Beecham Corp Derivados de 2-oxindol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos
US6635249B1 (en) * 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
US7860583B2 (en) * 2004-08-25 2010-12-28 Carefusion 303, Inc. System and method for dynamically adjusting patient therapy
CA2440387A1 (en) * 2001-03-23 2002-10-03 Durect Corporation Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space
US20040106954A1 (en) * 2002-11-15 2004-06-03 Whitehurst Todd K. Treatment of congestive heart failure
WO2004100987A2 (en) 2003-05-06 2004-11-25 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat neointimal hyperplasia
EP1851245B1 (en) * 2005-01-26 2012-10-10 Amgen Fremont Inc. Antibodies against interleukin-1 beta
US20060171948A1 (en) * 2005-02-02 2006-08-03 Weinstein Steven P Methods of using IL-1 antagonists to reduce C-reactive protein
WO2006084145A2 (en) * 2005-02-02 2006-08-10 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to reduce c-reactive protein
AU2006236439B2 (en) 2005-04-15 2012-05-03 Macrogenics, Inc. Covalent diabodies and uses thereof
CN101228188A (zh) * 2005-06-21 2008-07-23 佐马技术有限公司 IL-1β结合抗体及其片段
EP1940880A2 (en) * 2005-10-14 2008-07-09 Novo Nordisk A/S Treating diabetes using inhibitors of il-1
JP4524275B2 (ja) * 2006-09-01 2010-08-11 日本ポリプロ株式会社 ビニル基および極性基含有プロピレン系共重合体及びそれを用いる重合体の製造方法。
WO2008077145A2 (en) * 2006-12-20 2008-06-26 Xoma Technology Ltd. Treatment of il-1-beta related diseases

Also Published As

Publication number Publication date
AU2010253924B2 (en) 2015-01-22
WO2010138939A1 (en) 2010-12-02
US20100316651A1 (en) 2010-12-16
CA2763161A1 (en) 2010-12-02
KR20120061041A (ko) 2012-06-12
EP2435073A4 (en) 2013-03-27
SG176265A1 (en) 2012-01-30
AU2010253924A1 (en) 2012-01-19
BRPI1011228A2 (pt) 2019-09-24
JP2015120704A (ja) 2015-07-02
US20180155420A1 (en) 2018-06-07
SG2014014534A (en) 2014-07-30
SG10201500180RA (en) 2015-03-30
CN107243077A (zh) 2017-10-13
JP2012528796A (ja) 2012-11-15
EP2435073A1 (en) 2012-04-04
US20210009679A1 (en) 2021-01-14
MX2011012666A (es) 2011-12-16
IL216660A0 (en) 2012-02-29
EA201101643A1 (ru) 2012-12-28
NZ597024A (en) 2014-01-31
JP5763625B2 (ja) 2015-08-12
CN102573893A (zh) 2012-07-11
US10611832B2 (en) 2020-04-07

Similar Documents

Publication Publication Date Title
US10611832B2 (en) Cardiovascular related uses of IL-1β antibodies and binding fragments thereof
US20210032326A1 (en) Methods for the treatment of gout
JP5809338B2 (ja) 関節リウマチの治療のための方法
US9139646B2 (en) Methods for the treatment of uveitis with IL-1β binding antibodies
AU2015203141A1 (en) Methods for the treatment of gout
AU2013203560A1 (en) Cardiovascular related uses of IL-1beta antibodies and binding fragments thereof